Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy Among Patients 75 Years or Older
JAMA Cardiology Author Interviews
00:00
Composite Endpoints and Individual Outcomes
Bach reviews the composite outcome components and notes consistent favorable effects but no mortality reduction.
Play episode from 08:14
Transcript
